• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)双突变株的2019冠状病毒病(COVID-19)患者的心律失常发生率:三级医疗中心的经验

Incidence of arrhythmias in COVID-19 patients with double mutant strain of SARS-CoV-2 virus: A tertiary care experience.

作者信息

Varshney Amit, Agarwal Navneet

机构信息

Department of Medicine, United Institute of Medical Sciences, Prayagraj, U.P., India.

出版信息

Glob Cardiol Sci Pract. 2022 Dec 30;2022(3):e202216. doi: 10.21542/gcsp.2022.16.

DOI:10.21542/gcsp.2022.16
PMID:36660165
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9840134/
Abstract

Our understanding of arrhythmias is minimal with SARS-CoV-2 virus and with the emergence of its double mutant, virtually nonexistent. Patients with the double mutant (B.1.617) SARS-CoV infection had more cardiac manifestations, including arrhythmias and sudden death, than with the traditional variant. To determine the incidence of arrhythmias in COVID-19 patients with double mutant strain of SARS-CoV-2 virus (B.1.617). We describe a prospective observational study conducted in the Department of Medicine, United Institute of Medical Sciences, Prayagraj, Uttar Pradesh on patients admitted to the hospital during the period March 2021 to May 2021. Different type of arrhythmias were studied in the admitted patients. Sinus bradycardia is the most common arrhythmia, followed by atrial fibrillation. Malignant arrhythmias, such as ventricular tachycardia/ventricular fibrillation and Torsades de pointes due to QT prolongation, were present in small number of patients with high mortality outcomes. Sinus tachycardia and high-grade AV blocks were also present in some of the patients. Current literature lacks studies on arrhythmias secondary to COVID-19 (double mutant) strain and its possible mechanisms. This makes it difficult to distinguish between arrhythmias secondary to COVID-19 (double mutant) infection due to hypoxemia, dyselectrolytemia, SIRS, comorbidities, and medications or direct viral effects on the cardiomyocytes.

摘要

我们对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒所致心律失常的了解极少,而随着其双突变体的出现,这方面的了解几乎不存在。感染双突变体(B.1.617)SARS-CoV的患者比感染传统毒株的患者有更多的心脏表现,包括心律失常和猝死。为了确定感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒双突变株(B.1.617)的2019冠状病毒病(COVID-19)患者中心律失常的发生率。我们描述了一项前瞻性观察性研究,该研究于2021年3月至2021年5月期间在北方邦普拉亚格拉杰联合医学科学研究所医学部对入院患者进行。对入院患者研究了不同类型的心律失常。窦性心动过缓是最常见的心律失常,其次是心房颤动。少数患者出现恶性心律失常,如室性心动过速/心室颤动和因QT延长导致的尖端扭转型室速,这些患者死亡率很高。部分患者还出现窦性心动过速和高度房室传导阻滞。目前的文献缺乏关于继发于2019冠状病毒病(双突变体)毒株的心律失常及其可能机制的研究。这使得难以区分继发于2019冠状病毒病(双突变体)感染的心律失常是由低氧血症、电解质紊乱、全身炎症反应综合征、合并症、药物还是病毒对心肌细胞的直接作用所致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/698f/9840134/fecb5d1259f6/gcsp-2022-3-e202216-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/698f/9840134/51b7c2f60341/gcsp-2022-3-e202216-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/698f/9840134/852f088bd0c1/gcsp-2022-3-e202216-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/698f/9840134/fecb5d1259f6/gcsp-2022-3-e202216-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/698f/9840134/51b7c2f60341/gcsp-2022-3-e202216-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/698f/9840134/852f088bd0c1/gcsp-2022-3-e202216-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/698f/9840134/fecb5d1259f6/gcsp-2022-3-e202216-g003.jpg

相似文献

1
Incidence of arrhythmias in COVID-19 patients with double mutant strain of SARS-CoV-2 virus: A tertiary care experience.感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)双突变株的2019冠状病毒病(COVID-19)患者的心律失常发生率:三级医疗中心的经验
Glob Cardiol Sci Pract. 2022 Dec 30;2022(3):e202216. doi: 10.21542/gcsp.2022.16.
2
Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.人类冠状病毒感染相关心律失常的发生率及治疗:系统综述。
Eur J Clin Invest. 2021 Feb;51(2):e13428. doi: 10.1111/eci.13428. Epub 2020 Nov 26.
3
Arrhythmia in COVID-19.新型冠状病毒肺炎中的心律失常
SN Compr Clin Med. 2020;2(9):1430-1435. doi: 10.1007/s42399-020-00454-2. Epub 2020 Aug 14.
4
COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.新型冠状病毒肺炎与心律失常:心律失常特征及管理策略的全球视角
J Interv Card Electrophysiol. 2020 Nov;59(2):329-336. doi: 10.1007/s10840-020-00789-9. Epub 2020 Jun 3.
5
Cardiac arrhythmias in patients presenting with COVID-19 treated in Portuguese hospitals: A national registry from the Portuguese Association of Arrhythmology, Pacing and Electrophysiology.葡萄牙心律失常学、起搏和电生理学协会的全国登记处:葡萄牙医院治疗的 COVID-19 患者的心律失常。
Rev Port Cardiol (Engl Ed). 2021 Aug;40(8):573-580. doi: 10.1016/j.repce.2020.11.025.
6
Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval.症状性儿科 SARS-CoV-2 感染 PCR 阳性患者心律失常和心电图异常的发生率,包括校正 QT 间期的药物诱导变化。
Heart Rhythm. 2020 Nov;17(11):1960-1966. doi: 10.1016/j.hrthm.2020.06.033. Epub 2020 Jul 1.
7
A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).一种新的生物标志物——心脏电生理平衡指数(iCEB)——在药物诱发的心律失常中发挥着重要作用:超越QT间期延长和尖端扭转型室性心动过速(TdP)。
J Pharmacol Toxicol Methods. 2013 Sep-Oct;68(2):250-259. doi: 10.1016/j.vascn.2013.01.003. Epub 2013 Jan 19.
8
Prevalence of arrhythmia in COVID-19 patients with mild/moderate and severe illness: a prospective cohort study.新型冠状病毒肺炎轻症/普通型和重症患者心律失常的发生率:一项前瞻性队列研究。
Expert Rev Cardiovasc Ther. 2023 Jun;21(6):453-461. doi: 10.1080/14779072.2023.2216456. Epub 2023 May 25.
9
QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.QT 间期延长、尖端扭转型室性心动过速和 COVID-19 短期使用氯喹或羟氯喹导致的猝死:系统评价。
Heart Rhythm. 2020 Sep;17(9):1472-1479. doi: 10.1016/j.hrthm.2020.05.008. Epub 2020 May 11.
10
Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.药物性心律失常:美国心脏协会的科学声明。
Circulation. 2020 Oct 13;142(15):e214-e233. doi: 10.1161/CIR.0000000000000905. Epub 2020 Sep 15.

引用本文的文献

1
Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction.提升期望:维立西呱用于射血分数降低的心力衰竭
J Pharm Bioallied Sci. 2024 Dec;16(Suppl 4):S4010-S4012. doi: 10.4103/jpbs.jpbs_1392_24. Epub 2024 Dec 27.
2
Analysis of risk factors and short-term prognostic factors of arrhythmia in patients infected with mild/moderate SARS-CoV-2 Omicron variant.轻度/中度新型冠状病毒奥密克戎变异株感染者心律失常的危险因素及短期预后因素分析
Front Med (Lausanne). 2023 Jul 27;10:1186200. doi: 10.3389/fmed.2023.1186200. eCollection 2023.
3
A cross-sectional study of echocardiographic characteristics of patients diagnosed with SARS-CoV-2 delta strain.

本文引用的文献

1
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).COVID-19 住院患者使用羟氯喹(无论是否联合使用阿奇霉素)导致 QT 间期延长的风险。
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
2
COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management.新型冠状病毒肺炎的心血管流行病学、细胞发病机制、临床表现及治疗
Int J Cardiol Heart Vasc. 2020 Jul 14;29:100589. doi: 10.1016/j.ijcha.2020.100589. eCollection 2020 Aug.
3
一项关于确诊感染新冠病毒德尔塔毒株患者的超声心动图特征的横断面研究。
Glob Cardiol Sci Pract. 2023 Aug 1;2023(3):e202319. doi: 10.21542/gcsp.2023.19.
Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review.
COVID-19 住院患者中与严重疾病或 ICU 入院和死亡相关的心脏损伤:一项荟萃分析和系统评价。
Crit Care. 2020 Jul 28;24(1):468. doi: 10.1186/s13054-020-03183-z.
4
Covid-19 and the cardiovascular system: a comprehensive review.Covid-19 与心血管系统:全面综述。
J Hum Hypertens. 2021 Jan;35(1):4-11. doi: 10.1038/s41371-020-0387-4. Epub 2020 Jul 27.
5
COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.新型冠状病毒肺炎与心律失常:心律失常特征及管理策略的全球视角
J Interv Card Electrophysiol. 2020 Nov;59(2):329-336. doi: 10.1007/s10840-020-00789-9. Epub 2020 Jun 3.
6
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.接受羟氯喹和阿奇霉素治疗的新冠肺炎患者的QT间期。
Nat Med. 2020 Jun;26(6):808-809. doi: 10.1038/s41591-020-0888-2.
7
Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications.新型冠状病毒肺炎相关心房颤动:从流行病学关联到药物治疗意义。
J Cardiovasc Pharmacol. 2020 Aug;76(2):138-145. doi: 10.1097/FJC.0000000000000854.
8
Heart Brake: An Unusual Cardiac Manifestation of COVID-19.心脏骤停:新型冠状病毒肺炎一种不寻常的心脏表现
JACC Case Rep. 2020 Jul 15;2(9):1252-1255. doi: 10.1016/j.jaccas.2020.04.026. Epub 2020 May 3.
9
Myocardial injury and COVID-19: Possible mechanisms.心肌损伤与 COVID-19:可能的机制。
Life Sci. 2020 Jul 15;253:117723. doi: 10.1016/j.lfs.2020.117723. Epub 2020 Apr 28.
10
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.氯喹、羟氯喹和阿奇霉素对 SARS-CoV-2 感染患者校正 QT 间期的影响。
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.